Jump to Main Contents
研究所ロゴ

Home > Updates

Updates

Sep. 6, 2021
Molecular landscape of multi-step virus carcinogenesis revealed by multi-modal single-cell analysis
Aug. 17, 2021
Whole Genome Sequencing Finds Therapeutic Targets for Linitis Plastica-type Gastric Cancer
Jun. 2, 2021
SARS-CoV-2 antibody status in patients with cancer during the COVID-19 pandemic in Japan
May 14, 2021
NATIONAL CANCER CENTER AND EISAI COMMENCE JOINT RESEARCH AND DEVELOPMENT PROJECT “BASIC RESEARCH ON THE DRUG DISCOVERY AND DEVELOPMENT TO ACCELERATE DEVELOPMENT OF ANTICANCER DRUGS IN TREATMENT OF PATIENTS WITH RARE CANCERS AND REFRACTORY CANCERS”, USING PDX WITH HIGH PREDICTABILITY OF CLINICAL OUTCOMES, AND CANCER GENOME DATA
Apr. 9, 2021
Dr Hiroyuki Mano was awarded the 49th Fondation ARC Leopold Griffuel Prize for Clinical and Translational Cancer Research
Nov. 25, 2020
Hiroyoshi Nishikawa Elected AAAS Fellow
Nov. 17, 2020
Hiroyoshi Nishikawa Honoured with the 2020 SITC ‘Team Science Award’
Sep. 1, 2020
A novel biomarker for predicting clinical efficacy of PD-1 blockade therapies
Aug. 20, 2020
NCC joins GSK’s oncology development network
Jul. 3, 2020
The National Cancer Center, the National Center for Global Health and Medicine, and Sysmex Corporation Evaluate a SARS-CoV-2 Antibody Test with Support from the Japan Health Research Promotion Bureau
Mar. 2, 2020
HE Professor Tomasz Grodzki, Polish Senate Marshal visit
Feb. 26, 2020
WHO and IARC Cancer Reports Published
Feb. 17, 2020
Global Consortium Completes Tumor Analyses Project
Jan. 29, 2020
Clinical Trial Investigators visit NCC Hospital
Feb. 12, 2019
UK Genomics Delegation visit
Oct. 1, 2018
National Cancer Center Japan and Maruho Enter License Agreement and Research Collaboration Agreement for a Novel Analgesic for Stomatitis in Cancer Treatment
Jun. 27, 2018
Development of an integrated CRISPRi targeting ΔNp63 for treatment of squamous cell carcinoma
May 7, 2018
National Cancer Center and Carna Biosciences Announce Research Collaboration for new drug discovery
Feb. 14, 2018
A secondary RET mutation in the activation loop conferring
resistance to vandetanib through allosteric effects
Jan. 23, 2018
Precise cancer risk estimation based upon measurement of mutations and aberrant DNA methylation accumulated in normal tissues
association between the accumulation and life style